Moleculin secures Mexican patent protecting lung-targeted Annamycin through 2040
The company received a new patent from the Mexican Patent Office for its lung-targeted liposomal Annamycin formulation, bolstering its intellectual property portfolio ahead of a pivotal clinical trial in AML.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed